A Randomized Double-Blinded Placebo-Controlled Multi-Institutional Phase II.5 Study of Saracatinib (AZD0530) a Selective Src Kinase Inhibitor in Patients with Recurrent Osteosarcoma Localized to the Lung
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The main purpose of this research study is to determine if the addition of saracatinib can decrease the chance a tumor will come back.
Description
The main purpose of this research study is to determine if the addition of saracatinib can decrease the chance a tumor will come back.
Details
| Condition | Lung Cancer |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX1435 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.